Skip to main content
    C

    Catalyst Pharmaceuticals Inc (CPRX)

    Official site

    BIOTECHNOLOGY

    $31.49
    +0.00 (+0.00%)

    Last updated: Jul 16, 2026 at 5:00 PM ET

    Catalyst Pharmaceuticals Inc (CPRX) Financials: Revenue, Profit and Cash Flow

    Updated May 11, 2026. Financial statements from company filings, amounts in US dollars.

    Catalyst Pharmaceuticals reported revenue of $588.99M for the fiscal year ended Dec 31, 2025, up 19.8% from the year before. That year, net income was $214.33M with a net margin of 36.4%, operating cash flow was $208.67M and free cash flow was $208.61M. The quarter ended Mar 31, 2026 had revenue of $149.39M and net income of $63.73M.

    Revenue and Margins

    The operating margin was 43.8% in the fiscal year ended Dec 2025. Over the 7 years to Dec 2025, revenue grew from $500.00K, a compound annual rate of 174.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$588.99M+19.8%85.2%43.8%36.4%
    Dec 2024$491.73M+23.5%86.0%39.7%33.3%
    Dec 2023$398.20M+85.9%86.9%21.8%17.9%
    Dec 2022$214.20M+52.1%83.9%47.5%38.8%
    Dec 2021$140.83M+18.3%84.5%37.2%28.0%
    Dec 2020$119.07M+16.4%85.7%34.7%63.0%
    Dec 2019$102.31M+20361.2%85.6%31.1%31.2%
    Dec 2018$500.00KN/A100.0%-7059.0%-6800.7%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 30.8% from the year before. In the quarter ended Mar 2026, net income rose 12.3% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$588.99M$491.73M$398.20M$214.20M$140.83M$119.07M$102.31M$500.00K$0$0
    Cost of revenue$87.25M$68.84M$51.97M$34.39M$21.88M$17.04M$14.76M$0$0$0
    Gross profit$501.74M$422.89M$346.24M$179.81M$118.95M$102.03M$87.55M$500.00K$0$0
    Research and development$12.71M$12.65M$93.15M$19.79M$16.94M$16.50M$18.84M$19.92M$11.38M$11.37M
    Operating income$257.78M$195.12M$86.81M$101.84M$52.38M$41.30M$31.82M-$35.30M-$18.68M-$19.28M
    Net income$214.33M$163.89M$71.41M$83.08M$39.48M$74.98M$31.88M-$34.00M-$18.41M-$18.07M
    EBITDA$321.39M$254.04M$127.39M$105.96M$52.86M$41.98M$33.71M-$33.97M-$18.37M-$18.03M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$149.39M$152.61M$148.39M$146.56M$141.42M$141.82M$128.69M$122.71M$98.51M$110.57M$102.69M$99.58M
    Gross profit$134.91M$126.54M$125.74M$125.95M$123.51M$120.18M$109.42M$107.31M$85.99M$94.76M$88.52M$87.54M
    Operating income$73.23M$61.85M$66.27M$66.30M$63.37M$62.84M$50.91M$54.25M$27.13M$41.69M-$37.19M$46.70M
    Net income$63.73M$52.70M$52.78M$52.11M$56.74M$55.94M$43.88M$40.79M$23.27M$34.84M-$30.76M$37.76M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $437.00K by $708.73M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.10B$851.41M$470.11M$375.63M$237.79M$192.35M$112.38M$60.45M$85.39M$41.71M
    Current assets$894.03M$623.61M$219.33M$320.81M$210.11M$159.24M$111.36M$55.19M$85.19M$41.45M
    Cash and equivalents$709.17M$517.55M$137.64M$298.39M$171.44M$130.24M$89.51M$16.56M$57.50M$13.89M
    Total liabilities$149.71M$123.78M$82.23M$75.21M$30.96M$22.76M$24.75M$9.67M$4.42M$2.40M
    Short-term debt$437.00K$402.00K$369.00K$337.00K$308.00K$29.00K$300.52KN/AN/AN/A
    Shareholder equity$954.27M$727.63M$387.88M$300.42M$206.83M$169.60M$87.63M$50.78M$80.96M$39.31M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$1.15B$1.11B$1.05B$971.91M$908.87M$851.41M$772.01M$706.36M$646.68M$470.11M$413.21M$443.90M
    Total liabilities$134.91M$152.54M$131.36M$115.89M$114.59M$123.78M$111.07M$97.70M$85.26M$82.23M$64.66M$68.60M
    Cash and equivalents$755.86M$709.17M$689.89M$652.80M$580.66M$517.55M$442.33M$375.69M$310.41M$137.64M$120.97M$178.79M
    Shareholder equity$1.01B$954.27M$920.25M$856.03M$794.28M$727.63M$660.94M$608.65M$561.41M$387.88M$348.55M$375.29M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow. Share repurchases came to 12.1% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$208.67M$239.81M$143.60M$116.05M$60.37M$45.03M$34.61M-$26.15M-$13.74M-$17.96M
    Capital expenditures$58.00K$556.00K$231.00K$29.00K$1.02M$11.00K$19.00K$92.02K$92.02K$96.06K
    Free cash flow$208.61M$239.25M$143.37M$116.02M$59.35M$45.02M$34.59M-$26.24M-$13.83M-$18.06M
    Share repurchases$25.30M$296.00K$0$6.91M$12.09M$0$0N/AN/AN/A
    Investing cash flow-$58.00K-$556.00K-$293.50M$9.21M-$11.02M-$5.01M$37.23M-$15.08M-$3.96K$3.55M
    Financing cash flow-$16.99M$140.66M-$10.86M$1.69M-$8.14M$702.00K$1.12M$293.12K$57.35M$68.99K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow$59.59M$44.89M$32.44M$71.30M$60.04M$70.88M$72.87M$64.14M$31.93M$55.65M$45.13M$30.75M
    Capital expenditures$27.00K$32.00K$0$26.00K$0$88.00K$259.00K$10.00K$199.00K$93.00K$64.00K$0
    Free cash flow$59.56M$44.86M$32.44M$71.27M$60.04M$70.79M$72.61M$64.13M$31.73M$55.55M$45.06M$30.75M
    Last 12 quarters

    Frequently Asked Questions About CPRX

    What is Catalyst Pharmaceuticals' annual revenue?

    Catalyst Pharmaceuticals reported revenue of $588.99M for the fiscal year ended Dec 31, 2025.

    How fast is Catalyst Pharmaceuticals' revenue growing?

    Revenue was up 19.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 40.1%.

    Is Catalyst Pharmaceuticals profitable?

    Yes. Catalyst Pharmaceuticals reported net income of $214.33M for the fiscal year ended Dec 31, 2025, with a net margin of 36.4%.

    How much free cash flow does CPRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $208.67M minus capital expenditures of $58.00K produced free cash flow of $208.61M.

    How much debt does Catalyst Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $437.00K and cash and equivalents of $709.17M.